D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
86,500
+1,500 (1.76%)
May 30, 2025, 3:30 PM KST
222.76%
Market Cap 910.12B
Revenue (ttm) 10.75B
Net Income (ttm) -32.98B
Shares Out 10.71M
EPS (ttm) -3,151.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 120,317
Average Volume 399,629
Open 86,800
Previous Close 85,000
Day's Range 83,800 - 88,000
52-Week Range 25,100 - 94,800
Beta n/a
RSI 61.21
Earnings Date May 15, 2025

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.